These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

546 related items for PubMed ID: 24898552

  • 1. Catheter-based renal denervation for treatment of patients with treatment-resistant hypertension: 36 month results from the SYMPLICITY HTN-2 randomized clinical trial.
    Esler MD, Böhm M, Sievert H, Rump CL, Schmieder RE, Krum H, Mahfoud F, Schlaich MP.
    Eur Heart J; 2014 Jul; 35(26):1752-9. PubMed ID: 24898552
    [Abstract] [Full Text] [Related]

  • 2. Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
    Bhatt DL, Vaduganathan M, Kandzari DE, Leon MB, Rocha-Singh K, Townsend RR, Katzen BT, Oparil S, Brar S, DeBruin V, Fahy M, Bakris GL, SYMPLICITY HTN-3 Steering Committee Investigators.
    Lancet; 2022 Oct 22; 400(10361):1405-1416. PubMed ID: 36130612
    [Abstract] [Full Text] [Related]

  • 3. 12-month blood pressure results of catheter-based renal artery denervation for resistant hypertension: the SYMPLICITY HTN-3 trial.
    Bakris GL, Townsend RR, Flack JM, Brar S, Cohen SA, D'Agostino R, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL, SYMPLICITY HTN-3 Investigators.
    J Am Coll Cardiol; 2015 Apr 07; 65(13):1314-1321. PubMed ID: 25835443
    [Abstract] [Full Text] [Related]

  • 4. Percutaneous renal denervation in patients with treatment-resistant hypertension: final 3-year report of the Symplicity HTN-1 study.
    Krum H, Schlaich MP, Sobotka PA, Böhm M, Mahfoud F, Rocha-Singh K, Katholi R, Esler MD.
    Lancet; 2014 Feb 15; 383(9917):622-9. PubMed ID: 24210779
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety and performance of the second generation EnligHTN™ Renal Denervation System in patients with drug-resistant, uncontrolled hypertension.
    Worthley SG, Wilkins GT, Webster MW, Montarello JK, Delacroix S, Whitbourn RJ, Warren RJ.
    Atherosclerosis; 2017 Jul 15; 262():94-100. PubMed ID: 28531827
    [Abstract] [Full Text] [Related]

  • 8. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial.
    Esler MD, Krum H, Schlaich M, Schmieder RE, Böhm M, Sobotka PA, Symplicity HTN-2 Investigators.
    Circulation; 2012 Dec 18; 126(25):2976-82. PubMed ID: 23248063
    [Abstract] [Full Text] [Related]

  • 9. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial.
    Symplicity HTN-2 InvestigatorsBaker IDI Heart and Diabetes Institute, PO Box 6492, St Kilda Road, Central Melbourne, VIC 8008, Australia. murray.esler@bakeridi.edu.au, Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M.
    Lancet; 2010 Dec 04; 376(9756):1903-9. PubMed ID: 21093036
    [Abstract] [Full Text] [Related]

  • 10. Ultra-long-term efficacy and safety of catheter-based renal denervation in resistant hypertension: 10-year follow-up outcomes.
    Al Ghorani H, Kulenthiran S, Lauder L, Recktenwald MJM, Dederer J, Kunz M, Götzinger F, Ewen S, Ukena C, Böhm M, Mahfoud F.
    Clin Res Cardiol; 2024 Oct 04; 113(10):1384-1392. PubMed ID: 38451261
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Comparison of two different radiofrequency ablation systems for renal artery denervation: Evaluation of short-term and long-term follow up.
    Al Raisi SI, Pouliopoulos J, Qian P, King P, Byth K, Barry MT, Swinnen J, Thiagalingam A, Kovoor P.
    Catheter Cardiovasc Interv; 2019 Feb 15; 93(3):E105-E111. PubMed ID: 30549404
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Twelve-month results of the rapid renal sympathetic denervation for resistant hypertension using the OneShotTM ablation system (RAPID) study.
    Verheye S, Ormiston J, Bergmann MW, Sievert H, Schwindt A, Werner N, Vogel B, Colombo A.
    EuroIntervention; 2015 Feb 15; 10(10):1221-9. PubMed ID: 25452198
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study.
    Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M.
    Lancet; 2009 Apr 11; 373(9671):1275-81. PubMed ID: 19332353
    [Abstract] [Full Text] [Related]

  • 18. Effect of Catheter-Based Renal Denervation on Morning and Nocturnal Blood Pressure: Insights From SYMPLICITY HTN-3 and SYMPLICITY HTN-Japan.
    Kario K, Bhatt DL, Brar S, Cohen SA, Fahy M, Bakris GL.
    Hypertension; 2015 Dec 11; 66(6):1130-7. PubMed ID: 26558819
    [Abstract] [Full Text] [Related]

  • 19. Sufficient and Persistent Blood Pressure Reduction in the Final Long-Term Results From SYMPLICITY HTN-Japan　- Safety and Efficacy of Renal Denervation at 3 Years.
    Kario K, Yamamoto E, Tomita H, Okura T, Saito S, Ueno T, Yasuhara D, Shimada K, SYMPLICITY HTN-Japan Investigators.
    Circ J; 2019 Feb 25; 83(3):622-629. PubMed ID: 30760655
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.